Glenmark Pharmaceuticals Limited (GLENMARK.BO)
- Previous Close
1,042.70 - Open
1,029.65 - Bid --
- Ask --
- Day's Range
1,020.60 - 1,038.70 - 52 Week Range
507.65 - 1,068.00 - Volume
21,850 - Avg. Volume
44,786 - Market Cap (intraday)
289.285B - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-27.06 - Earnings Date May 16, 2024 - May 30, 2024
- Forward Dividend & Yield 2.50 (0.24%)
- Ex-Dividend Date Sep 18, 2023
- 1y Target Est
601.93
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India.
www.glenmarkpharma.com15,556
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: GLENMARK.BO
Performance Overview: GLENMARK.BO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLENMARK.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLENMARK.BO
Valuation Measures
Market Cap
289.29B
Enterprise Value
327.60B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.25
Price/Book (mrq)
3.10
Enterprise Value/Revenue
2.55
Enterprise Value/EBITDA
61.74
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.41%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
131.58B
Net Income Avi to Common (ttm)
-7.64B
Diluted EPS (ttm)
-27.06
Balance Sheet and Cash Flow
Total Cash (mrq)
11.24B
Total Debt/Equity (mrq)
53.22%
Levered Free Cash Flow (ttm)
--